A recombinant humanized type III collagen coating achieved 71.68% endothelialization at 40 days post-implantation in vivo, nearly double that of unmodified controls.
Does a recombinant humanized type III collagen coating improve endothelialization and reduce inflammation compared to unmodified controls in left atrial appendage closure devices?
A novel recombinant humanized type III collagen coating for LAA occluders significantly enhances endothelialization and modulates inflammation in preclinical models, offering a promising strategy to reduce post-implant complications.
Abstract Transcatheter cardiac occluders represent a mainstay minimally invasive therapy for congenital heart disease and preventing left atrial appendage-related thrombosis. However, their long-term clinical efficacy is constrained by frequent post-implant complications, including device-related thrombosis, persistent inflammation, incomplete reendothelialization, and delayed tissue healing. Herein, we developed a hierarchical functional modification strategy for biodegradable polymers, via stable covalent grafting of recombinant humanized type III collagen (rhCol III)—a biomaterial with robust cell adhesiveness and low immunogenicity—onto the polymer surface. Systematic in vitro assays demonstrated that the rhCol III coating effectively inhibited coagulation, enhanced endothelial and cardiomyocyte function, and modulated inflammation through promoting the polarization of macrophages to the anti-inflammatory M2 phenotype. In vivo, this innovative coating achieved 71.68% endothelialization at 40 days post-implantation, nearly double that of unmodified controls, and transcriptomic analysis further validated its acceleration of reendothelialization and tissue healing. Collectively, this multifunctional rhCol III coating integrates anticoagulant, anti-inflammatory, and pro-endothelialization properties, providing a promising translational strategy to advance left atrial appendage occluders from passive mechanical occlusion to active biofunctional regeneration.
Zhou et al. (Thu,) conducted a other in Congenital heart disease and left atrial appendage-related thrombosis. Recombinant humanized type III collagen (rhCol III) coating vs. Unmodified controls was evaluated on Endothelialization. A recombinant humanized type III collagen coating achieved 71.68% endothelialization at 40 days post-implantation in vivo, nearly double that of unmodified controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: